Clovis Oncology is advancing the fight against cancer. Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer. Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado. Please visit our website for more information, including additional office locations in the U.S. and Europe.
Location: United States, Colorado, Boulder
Employees: 201-500
Total raised: $275M
Founded date: 2009
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.06.2013 | - | $275M | - |
Mentions in press and media 16
| Date | Title | Description |
| 21.03.2026 | Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies | Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-20... |
| 17.03.2026 | Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic | Mestag Therapeutics, a biotech company focused on fibroblast immunology, has announced the closing of a $40 million financing round, bringing its total funding to more than $95 million. The round was backed by SV Health Investors, Johnson &... |
| 04.10.2022 | Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim | Pfizer acquired both Xtandi and Talzenna, a PARP inhibitor, in its $14 billion buyout of Medivation in 2016. And in its Phase III TALAPRO-2 study, it combined the two drugs to treat patients with metastatic castration-resis... |
| 31.03.2022 | Clovis Stock Is Soaring. The Biotech’s Ovarian Cancer Drug Looks Promising. | Shares of the small biotech firm Clovis Oncology jumped more than 40% on Thursday, after the company reported positive data in a late-stage trial of its drug Rubraca in women with ovarian cancer. The study found that Rubraca improved progre... |
| 24.08.2021 | Clovis Oncology : Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland | Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision of therapeutic products (Swissmedic)i gave a... |
| 19.03.2021 | Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation | BOULDER, Colo.--(BUSINESS WIRE)--Mar 19, 2021-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca ® (rucaparib) will take place today in an oral presentat... |
| 18.05.2020 | Clovis' Rubraca wins prostate cancer approval, but data from rival Lynparza dampen commercial expectations | While AstraZeneca and Merck’s market-leading Lynparza seemingly pipped Clovis Oncology’s rival Rubraca in helping prostate cancer patients, Rubraca has, as expected, made it across the finish line first. On Friday, the ... |
| 03.12.2018 | GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billion | Tesaro’s only marketed product is Zejula (niraparib), a PARP inhibitor approved for the maintenance treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer, following a response to treatment with platinum-based chemother... |
| 25.03.2015 | This entrepreneur nearly lost his company. Here’s how litigation finance helped him fight back | In 2009, Chant, who had previously founded G-Zero Therapeutics (now G-One Therapeutics), heard about some tremendously promising technology being developed by researchers at the Dana-Farber Cancer Institute. It was a cancer drug candidate c... |
| 20.11.2013 | Clovis Oncology Acquires Ethical Oncology Science for up to $415M | Clovis Oncology (NASDAQ:CLVS), a Boulder, Colorado-based biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets, has acquired EOS... |
Show more